TABLE 3

Results of Organ Distribution Experiments at 1 Hour After Injection

Uptake (%ID/g) in:
OrganLNCaP tumor, no blockadeLNCaP tumor, 2-PMPA blockadePC-3 tumor, PSMA-negative
Blood0.60 ± 0.210.41 ± 0.130.77 ± 0.29
Heart1.11 ± 0.200.41 ± 0.071.45 ± 0.10
Lung1.25 ± 0.270.78 ± 0.042.09 ± 0.33
Spleen6.99 ± 1.041.40 ± 0.2712.44 ± 5.98
Liver1.06 ± 0.200.43 ± 0.031.14 ± 0.16
Kidney84.03 ± 13.859.72 ± 2.50142.08 ± 25.82
Muscle0.79 ± 0.280.40 ± 0.190.94 ± 0.47
Small intestine0.90 ± 0.210.46 ± 0.101.20 ± 0.18
Brain0.12 ± 0.040.07 ± 0.030.10 ± 0.01
Tumor8.04 ± 2.394.26 ± 2.061.05 ± 0.11
  • All mice were injected with 1–2 MBq of 18F-PSMA-1007 (carrier added; 60 pmol/injection). Mice bore either PSMA-positive LNCaP or PSMA-negative PC-3 tumors. In blockade experiment, tracer was injected 30 min after administration of 40 nmol of 2-PMPA (n = 3 mice per column). Data are mean ± SD.